Abstract
Background Statins are commonly prescribed to lower LDL cholesterol. Clinical guidelines recommend 30-50% reduction within 3 months, yet many patients do not achieve this. We investigated the impact of patient characteristics and genetics on LDL-c reduction, treatment adherence, and adverse clinical outcomes.
Methods We analysed 76,000 UK Biobank participants prescribed atorvastatin or simvastatin in primary care: 41,000 had LDL-c measurements before statin initiation (median=16 days prior, IQR=28) and within a year of starting treatment (median=89 days, IQR=125). Adherence was defined as the “proportion of days covered” (PDC). We estimated associations between PDC within one year of statin initiation, genetic factors, post-treatment LDL reduction, and clinical adverse outcomes. For 13,000 patients with ≥3 LDL-c measures, we used inverse probability weighting methods to estimate the effect of sustained adherence intervention on LDL-c reduction longitudinally.
Results Predictors of LDL-c reduction following statin initiation included the time until the 1st measurement, PDC, and the pharmacogenetic variant SLCO1B1*5. LDL-c reduction was greater in those with high adherence versus lower adherence (38% reduction when PDC>95% [high] vs. 15% when PDC<50% [low]). Longitudinal causal modelling showed that the most recent PDC measure exerted the largest influence on overall LDL-c reduction, followed by the initial PDC.
Genetic predictors of reduced PDC included liability to schizophrenia (Coeftop 20%-1.94, 95%CI -2.69 to -1.19), whilst genetic liability to cardiovascular diseases increased PDC (Coeftop 20%1.30, 95%CI 0.55 to 2.05). High PDC was associated with increased risk of incident iron deficiency anaemia (HR 1.30, 95%CI 1.09-1.54) and cataract (HR 1.20, 95%CI 1.07-1.34), and decreased risk of incident coronary heart disease (HR 0.78, 95%CI 0.73-0.84).
Conclusion We identify substantial variability in the time to first on-treatment LDL measurements and also in adherence to statin medication, highlighting a gap between NHS guidelines, LDL monitoring and statin adherence. We show its subsequent impact on long term health, demonstrating the potential effect of targeted interventions to improve adherence. We identify important predictors of reduced statin effectiveness, including pharmacogenetic variants, polygenic scores, but most of all, adherence. Tailored statin therapy strategies with patient education on statin indication and adherence could optimise treatment efficacy, safety, and long-term clinical outcomes.
Competing Interest Statement
JB is employed part-time by Novo Nordisk, his company work is unrelated to that presented here. DG is the Chief Executive Officer of Sequoia Genetics, a private company that works with investors, pharma, biotech, and academia by performing research that leverages genetic data to help inform drug discovery and development. DG serves on the advisory board of, and has financial interests in, several biotechnology companies, his company work is unrelated to that presented here.
Funding Statement
DT, XL, DG, LCP, and JB are funded by UK Medical Research Council research grant MR/X011372/1. JM is funded by a National Institute for Health Research Fellowship (NIHR301445). This publication presents independent research funded by the National Institute for Health Research (NIHR). This study is supported by the NIHR Exeter Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The funders had no involvement in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The collection and use of UK Biobank data was approved by the North West Multi-Centre Research Ethics Committee (Research Ethics Committee reference 11/NW/0382). Access to UK Biobank was granted under Application Number 14631.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.